Terms: = Lymphoma AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7
6944 results:
1. Advancements in cancer immunotherapies targeting cd20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract] [Full Text] [Related]
2. Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report.
Yan X; Ren W; Li S; Zhu Z; Gao L; Zhi K
BMC Oral Health; 2024 Apr; 24(1):470. PubMed ID: 38637781
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
Qadir MI; Ahmed B; Hussain N
Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
[TBL] [Abstract] [Full Text] [Related]
4. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract] [Full Text] [Related]
5. Splenic B-cell lymphoma/leukemia with prominent nucleoli: A three-case series of the newly named old entity and review of literature.
Rai V; Saha A; Gondha S; Manimaran P; Sawhney J
J Cancer Res Ther; 2024 Jan; 20(1):315-320. PubMed ID: 38554340
[TBL] [Abstract] [Full Text] [Related]
6. Establishment of cluster of differentiation 20 immobilized cell membrane chromatography for the screening of active antitumor components in traditional Chinese medicine.
Ding Y; Guo N; Jiang Y; Liu S; Zhou T; Bai H; Lv Y; Han S; He L
J Chromatogr A; 2024 Apr; 1721():464845. PubMed ID: 38552371
[TBL] [Abstract] [Full Text] [Related]
7. Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
McIlroy G; Lax S; Gaskell C; Jackson A; Rhodes M; Seale T; Fox S; Hopkins L; Okosun J; Barrington SF; Ringshausen I; Ramsay AG; Calaminici M; Linton K; Bishton M
BMC Cancer; 2024 Mar; 24(1):370. PubMed ID: 38528445
[TBL] [Abstract] [Full Text] [Related]
8. [Studies on clinicopathological features of duodenal-type follicular lymphoma of 18 patients].
Du YR; Li J; Li SX; Guan CY; Li HL; Gao ZF; Li X; Dong GH
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):94-97. PubMed ID: 38527846
[TBL] [Abstract] [Full Text] [Related]
9. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a cd20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
[TBL] [Abstract] [Full Text] [Related]
10. From the archives of MD Anderson Cancer Center: Monomorphic epitheliotropic intestinal T-cell lymphoma: A case with an unusual immunophenotype and discussion of differential diagnosis.
Dcunha NJ; Wei Q; Thakral B; Medeiros LJ
Ann Diagn Pathol; 2024 Jun; 70():152293. PubMed ID: 38484479
[TBL] [Abstract] [Full Text] [Related]
11. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases.
FASEB J; ; . PubMed ID: 38470360
[TBL] [Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next]
